
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **April 12, 2013**

LANTHEUS MEDICAL IMAGING, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation)

333-169785
(Commission File Number)

51-0396366
(IRS Employer Identification No.)

331 Treble Cove Road, North Billerica, MA 01862
(Address of principal executive offices) (Zip code)

Registrant's telephone number, including area code: **(978) 671-8001**

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-
-

Item 5.02 **Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On April 15, 2013, the registrant, Lantheus Medical Imaging, Inc. (the “Company”), announced the transition of Cyrille Villeneuve to the Company’s Vice President, International, effective April 15, 2013, from his prior position as the Company’s Chief Commercial Officer.

Item 8.01 **Other Events.**

On April 15, 2013, the Company also announced the appointment of Mary Anne Heino as the Company’s new Chief Commercial Officer and Michael Heslop as the Company’s new Vice President, Business Development and Strategic Planning. Prior to the realignment, Mr. Heslop served as the Company’s Vice President, International from June 2012 to April 2013.

A copy of the Company’s press release, dated April 15, 2013, announcing the realignment of the Company’s executive leadership team is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01 **Financial Statements and Exhibits.**

(d) Exhibits

Exhibit Number	Description of Exhibits
99.1	Press Release, dated April 15, 2013, announcing the realignment of the Company’s executive leadership team.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LANTHEUS MEDICAL IMAGING, INC.

By: /s/ Michael P. Duffy
Name: Michael P. Duffy
Title: Vice President and Secretary

Date: April 16, 2013

EXHIBIT LIST

**Exhibit
Number**

Description of Exhibits

99.1

Press Release, dated April 15, 2013, announcing the realignment of the Company's executive leadership team.



331 Treble Cove Road
North Billerica, MA 01862

800.362.2668
www.lantheus.com

FOR IMMEDIATE RELEASE

CONTACTS:

Lantheus Medical Imaging

Linda Lennox
978-671-8854
linda.lennox@lantheus.com

Meara Murphy
978-671-8508
meara.murphy@lantheus.com

Pure Communications

Michele Rozen
617-730-8284

LANTHEUS MEDICAL IMAGING REALIGNS EXECUTIVE LEADERSHIP TEAM

Mary Anne Heino Joins Company as New Chief Commercial Officer;

Company Positioned to Optimize Growth

No. BILLERICA, Mass. (April 15, 2013)— Lantheus Medical Imaging, Inc., a global leader in developing, manufacturing and distributing innovative diagnostic imaging agents, today announced the Company is realigning its executive management team to optimize growth of the organization. To infuse new talent into the Company, Mary Anne Heino has been appointed as the new Chief Commercial Officer, effective April 15, 2013. Ms. Heino brings to the Company significant expertise and leadership in all facets of pharmaceutical and biotech commercial operations across multiple therapeutic markets. In her new role, Ms. Heino will be responsible for Global Sales & Marketing.

As part of the realignment, Mike Heslop, formerly Vice President, International, will become the Company's new Vice President, Business Development and Strategic Planning, a role that will focus on leading strategic partnerships, including for Lantheus' most advanced clinical candidate, flurpiridaz F 18, and driving key commercial initiatives. Additionally, Cyrille Villeneuve, formerly Chief Commercial Officer, will move to the role of Vice President, International, to focus on growing the Company's international business.

"Growing our business, both in the U.S. and internationally, and successfully partnering our pipeline of innovative diagnostic imaging agents are top priorities for the Company," said Jeff Bailey, Chief Executive Officer. "By adding new top talent and optimizing the strengths of our existing management team, we can effectively enhance our capabilities and focus on our critical drivers to align Lantheus for further success."

Ms. Heino is well positioned to lead the Company's Global Sales & Marketing organization with nearly 25 years of pharmaceutical sales and marketing leadership, including progressive executive experience with Centocor, Inc. and Janssen Pharmaceutica during her 18-year tenure with the Johnson & Johnson Family of Companies. While at Centocor, she led both the Cardiovascular and Immunology sales forces, as well as key areas of Commercial Operations. Recently, she served as President of Angelini Labopharm, an international pharmaceutical joint venture. Ms. Heino received a B.S. in Nursing from the City University of New York, a B.S. in Biology from Stony Brook University, and an M.B.A. from The Stern School of Business at New York University.

About Lantheus Medical Imaging, Inc.

Lantheus Medical Imaging, Inc., a global leader in developing, manufacturing and distributing innovative diagnostic imaging agents, is dedicated to creating and providing pioneering medical imaging solutions to improve the treatment of human disease. The Company's proven success in the field of diagnostic imaging provides a strong platform from which to bring forward breakthrough new tools for the diagnosis and management of disease. Lantheus imaging products include the echocardiography contrast agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension, an ultrasound contrast agent for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border, TechnoLite® (Technetium Tc99m Generator), Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), and Thallium 201 (Thallous Chloride Tl 201 Injection). Lantheus has approximately 600 employees worldwide with headquarters in North Billerica, Massachusetts, and offices in Puerto Rico, Canada and Australia. For more information, visit www.lantheus.com.

Safe Harbor for Forward-Looking and Cautionary Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks and uncertainties that may be described from time to time in our filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

###
